Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) is thrilled to announce that it will be participating in the Jefferies Healthcare Conference in New York City on June 7-8, 2023! This biopharmaceutical company is dedicated to creating novel therapeutics to fight progressive non-viral liver diseases, and is eager to share their research and accomplishments with a diverse audience of investors. Be sure to join Intercept Pharmaceuticals as they continue to make strides in developing drug treatments that could revolutionize the pharmaceutical industry.
For those attending the conference who want to connect with the Intercept management team, don’t hesitate to get in touch with Nareg Sagherian to see about arranging a meeting. Investing your time to meet the team can give you an inside perspective on Intercept’s operations and more insight into how the company is positioned in the market. Don’t miss this opportunity to learn more
Intercept Pharmaceuticals is on a mission to revolutionize the treatment of progressive non-viral liver diseases, such as primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), and severe alcohol-associated hepatitis (sAH). Through innovative drug discoveries and commercialization, Intercept is set to bring hope to countless patients suffering from debilitating liver diseases.